1301660-75-2

Upstream product

• 825643-73-0 2-(3,5-bis(trifluoromethyl)phenyl)-N-(6-chloro-4-(4-fluoro-2-methylphenyl)pyridin-3-yl)-N,2-dimethylpropanamide 
• 1301660-56-9 2-[3,5-bis(trifluoromethyl)phenyl]-N-[4-(4-fluoro-2-methylphenyl)-6-formyl-3-pyridinyl]-N,2-dimethylpropanamide 
• 1301660-54-7 2-[3,5-bis(trifluoromethyl)phenyl]-N-[6-ethenyl-4-(4-fluoro-2-methylphenyl)-3-pyridinyl]-N,2-dimethylpropanamide 
• 1301660-74-1 diethyl 2-{[5-[{2-[3,5-bis(trifluoromethyl)phenyl]-2-methylpropanoyl}-(methyl)amino]-4-(4-fluoro-2-methylphenyl)-2-pyridinyl]carbonyl}butanedioate 
• 1301660-72-9 ethyl 3-[5-[{2-[3,5-bis(trifluoromethyl)phenyl]-2-methylpropanoyl}-(methyl)amino]-4-(4-fluoro-2-methylphenyl)-2-pyridinyl]-3-oxopropanoate 
• 1301660-71-8 methyl 5-[{2-[3,5-bis(trifluoromethyl)phenyl]-2-methylpropanoyl}-(methyl)amino]-4-(4-fluoro-2-methylphenyl)-2-pyridinecarboxylate 
• 1301660-69-4 5-[{2-[3,5-bis(trifluoromethyl)phenyl]-2-methylpropanoyl}(methyl)amino]-4-(4-fluoro-2-methylphenyl)-2-pyridinecarboxylic acid 

Downstream Products

• 1301660-04-7 2-[3,5-bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[3-(hydroxymethyl)-5-oxo-2-pyrrolidinyl]-3-pyridinyl}-N,2-dimethylpropanamide 
• 1301660-03-6 2-[3,5-bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[3-(hydroxymethyl)-5-oxo-2-pyrrolidinyl]-3-pyridinyl}-N,2-dimethylpropanamide 
• 1301660-05-8 2-[3,5-bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[3-(hydroxymethyl)-5-oxo-2-pyrrolidinyl]-3-pyridinyl}-N,2-dimethylpropanamide 
• 1301660-07-0 2-[3,5-bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[3-(hydroxymethyl)-5-oxo-2-pyrrolidinyl]-3-pyridinyl}-N,2-dimethylpropanamide 

Relevant academic research and scientific papers

NOVEL LACTAM COMPOUNDS

There are provided according to the invention novel compounds of formula (I) or a pharmaceutically acceptable salt thereof: wherein R is halogen, C1-4 alkyl or trifluoromethyl; R1, R2, R7, R8, R9

Identification of novel NK1/NK3 dual antagonists for the potential treatment of schizophrenia

During the lead optimization of NK1/NK3 receptor antagonists program, a focused exploration of molecules bearing a lactam moiety was performed. The aim of the investigation was to identify the optimal position of the carbonyl and hyd